185 results on '"Manzella, Livia"'
Search Results
2. Multiple primary malignances managed with surgical excision: a case report with next generation sequencing analysis
3. PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance
4. In Silico Prediction of BRCA1 and BRCA2 Variants with Conflicting Clinical Interpretation in a Cohort of Breast Cancer Patients.
5. HER2-Low Expression in Male Breast Cancer: Results from a Multicenter Series in Italy
6. High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability
7. Single-Cell Analysis in the Omics Era: Technologies and Applications in Cancer
8. Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells
9. Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports
10. Supplementary Figure 1 from Suppression of Survivin Induced by a BCR-ABL/JAK2/STAT3 Pathway Sensitizes Imatinib-Resistant CML Cells to Different Cytotoxic Drugs
11. Data from Suppression of Survivin Induced by a BCR-ABL/JAK2/STAT3 Pathway Sensitizes Imatinib-Resistant CML Cells to Different Cytotoxic Drugs
12. Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far
13. Supplementary Figure 4 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
14. Supplementary Table 2 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
15. Supplementary Figure 2 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
16. Supplementary Figure 5 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
17. Supplementary Figure 1 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
18. Supplementary Figure 3 from High BCR–ABL/GUSIS Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose Imatinib
19. High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability
20. Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far
21. Male Breast Cancer Risk Associated with Pathogenic Variants in Genes Other than BRCA1/2: An Italian Case-Control Study
22. Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
23. Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients
24. Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience
25. Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily
26. A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic Applications
27. Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions
28. Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer
29. Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells
30. A Novel System for Semiautomatic Sample Processing in Chronic Myeloid Leukaemia: Increasing Throughput without Impacting on Molecular Monitoring at Time of SARS-CoV-2 Pandemic
31. The other side of the coin: dissecting molecular mechanisms behind hereditary breast cancer in search of therapeutic opportunities
32. Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer
33. Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts
34. AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?
35. Activation of the S100A7/RAGE Pathway by IGF-1 Contributes to Angiogenesis in Breast Cancer
36. Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma
37. Molecular Pathogenesis and Treatment Perspectives for Hypereosinophilia and Hypereosinophilic Syndromes
38. Microenvironmental Determinants of Breast Cancer Metastasis: Focus on the Crucial Interplay Between Estrogen and Insulin/Insulin-Like Growth Factor Signaling
39. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives
40. Combined use of sonographic and elastosonographic parameters can improve the diagnostic accuracy in thyroid nodules at risk of malignancy at cytological examination
41. Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma
42. Optimal Response in a Patient With CML Expressing BCR–ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report
43. Implications of Antidepressants Use in Breast Cancer: A Brief Review
44. Targeting BCL-2 as a Therapeutic Strategy for Primary p210BCR-ABL1-positive B-ALL Cells
45. Detection and Clinical Implications of a Novel BCR-ABL1 E12A2 Insertion/Deletion in a CML Patient Expressing the E13A2 Isoform
46. Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report
47. Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice
48. BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
49. Rapid decline of Philadelphia‑positive metaphases after nilotinib treatment in a cml patient expressing a rare e14a3 bcr‑abl1 fusion transcript: A case report
50. Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.